Latest Competition News

Maximus Resources Limited has issued a Target's Statement recommending shareholders accept Astral Resources NL's off-market takeover bid, which offers a significant premium and improved liquidity. The offer, valuing Maximus shares at approximately $0.073 each, aims to consolidate gold assets in Western Australia under Astral's larger portfolio.

VanEck Investments Limited has released its indicative dividends calendar for 2025, outlining expected dividend timings for over 50 exchange-traded funds (ETFs). This comprehensive schedule offers investors clarity on dividend announcements, ex-dates, and payment dates across a diverse range of funds.

Simonds Group delivered a resilient $13.6 million EBITDA in 1H FY25 amid a soft residential market and announced a strategic acquisition of Dennis Family Homes to fuel future growth.

Simonds Group reported a resilient first half of FY25 with EBITDA growth despite market softness and announced a strategic acquisition to strengthen its market position.

HiTech Group has reported a robust first half for FY2025, with net profit before tax up 14% and EBITDA rising 8%, underpinned by strong demand for ICT talent and services. The company also declared a fully franked interim dividend of 5 cents per share, signaling confidence in its growth trajectory.

HiTech Group Australia Limited has reported a robust half-year performance with a 29% increase in net profit and a strategic focus on high-margin ICT services amid growing market demand.

Althea Group Holdings has raised $4 million through a share and loan note placement to boost its THC beverage production and infrastructure across North America, targeting rapid growth in the U.S. and Canada.

Winsome Resources has raised approximately A$7.8 million through a placement to advance its flagship Adina Lithium Project and extend the Renard Option to August 2025, with plans for an additional share purchase plan targeting A$2.5 million.

PYC Therapeutics has launched a A$145.8 million pro-rata accelerated non-renounceable entitlement offer to fund late-stage clinical trials across its pipeline targeting rare diseases with high unmet needs. The capital raise aims to extend the company’s cash runway beyond FY27, supporting four drug candidates through critical human safety and efficacy milestones.

PYC Therapeutics is set to raise up to $146 million through a pro-rata entitlement offer, aiming to accelerate its RNA-based drug candidates targeting major unmet medical needs. Major shareholder support and underwriting commitments underpin the capital raise.

Mont Royal Resources has voluntarily suspended its shares on the ASX pending a critical announcement about a proposed re-compliance transaction, signaling a pivotal moment for the mining company.

Perpetual Limited has received updated, non-binding proposals from KKR for its Wealth Management and Corporate Trust businesses, but key terms and shareholder proceeds remain uncertain.